Roche Trial Met Primary Endpoint in IgA Nephropathy
The company plans to seek regulatory approval after the drug successfully reduced protein in patient urine samples.
Updated on Sept. 23, 2026 in Biotech
Live Poll
Should government prioritize the approval of high-cost specialty drugs over lower-cost existing treatment alternatives?
Roche reported that its drug sefaxersen met its primary endpoint in a phase 3 clinical trial for IgA nephropathy at the Week 37 interim analysis. The study showed that monthly subcutaneous injections reduced proteinuria in patients compared to a placebo.
Why it matters
The trial result advances a potential new treatment for IgA nephropathy, a condition where complement factor B damage impairs kidney function. Roche now aims to discuss accelerated approval pathways with regulators following these findings.
Sefaxersen is an antisense oligonucleotide—a strand of genetic material that blocks the production of specific proteins—designed to inhibit complement factor B. The study utilized the 24-hour protein-to-creatinine ratio to measure therapeutic efficacy.
The players
Roche
A global healthcare company focused on diagnostics and pharmaceuticals with a heavy emphasis on oncology and nephrology pipelines.
Ionis Pharmaceuticals
A biotechnology firm that specializes in antisense oligonucleotide therapeutics and licensed the sefaxersen program to Roche.
GSK
A multinational pharmaceutical company that previously held rights to the sefaxersen program before exiting in 2017.
The details
Sefaxersen acts by preventing the synthesis of complement factor B, a protein that contributes to the destruction of kidney cells in patients with IgA nephropathy. Patients in the study received monthly subcutaneous injections throughout the trial duration. While the current findings show a reduction in proteinuria, researchers will continue monitoring patients to evaluate actual changes in kidney function at Week 105.
Timeline
2017: GSK abandoned the development program.
2018: Roche paid $75 million to secure an option on the asset.
2022: Roche licensed sefaxersen for a $55 million upfront payment.
Week 37: Trial met its primary endpoint during the interim analysis.
The Tech Race
This development places Roche in direct competition with existing IgAN treatments like Fabhalta, which received FDA authorization in 2026. While analysts forecast 400 million euros in sales by 2030, Roche holds a higher peak estimate of 1 billion to 2 billion euros for the asset.
Patients and clinicians should monitor for upcoming regulatory filings as Roche initiates discussions on approval pathways. No timeline for commercial availability or specific pricing has been announced at this research stage.
The takeaway
Roche has successfully hit a major clinical milestone, confirming the efficacy of its complement-targeting approach in treating IgA nephropathy. Stakeholders should track the Week 105 data readout for definitive evidence of long-term kidney function preservation.
Further reading
For broader trends in renal medicine, visit our Biotech section.
Live Poll
Should government prioritize the approval of high-cost specialty drugs over lower-cost existing treatment alternatives?
